Company Research Report: Intelligencia AI
Company Overview
Name: Intelligencia AI
Mission: Empower life sciences companies to accelerate clinical development and de-risk business decisions with AI-driven solutions.
Founded: 2017 by Aiman Shalabi and Dimitrios Skaltsas
Key People:
- Dimitrios Skaltsas: CEO & Co-Founder
- Alexandra Ferraro: Head of Marketing
- Antonis Stampoulis: Director of Engineering
- Edoardo Madussi: Head of Business Development
- Elena Valkana: Senior Growth Associate
- Gerry Liaropoulos: Director of Data Science
- Heracles Kasimis: Director of Engineering
- Maria Georganaki: Director of Product
- Nikos Papadopoulos: Director of Finance
- Panos Karelis: Director of Insights Excellence
- Phoebe Prosalika: Director of People Operations
Headquarters: New York, NY, with offices in San Francisco, CA, and Athens, Greece.
Number of Employees: 110 individuals globally
Revenue: No information is available
Known For: Leading the way in leveraging proprietary data, biomedical expertise, and artificial intelligence (AI) to address challenges in the pharmaceutical industry, such as lengthy drug development timelines, high costs, and unsustainable ROI.
Products
Intelligencia Portfolio Optimizer™
High-Level Description: A patented SaaS platform that provides on-demand access to AI-powered insights based on best-in-class, proprietary data to assess the probability of success (PoS) and phase transition probabilities.
Key Features:
- AI-Powered Insights: Objectively assess PTRS and phase transitions.
- On-Demand Access: Provides continuous, real-time data.
- Dynamic Benchmarks: Focuses on specific indication and phase opportunities.
- Explainable AI: Transparency in AI processes to understand the driving factors behind assessments.
- Comprehensive Data: Access to meticulously curated and harmonized data.
Recent Developments
New Patents
- Intelligencia AI awarded U.S. Patent No. 11,948,667 (April 2, 2024) for innovative techniques in training and leveraging machine learning models to predict FDA approval likelihood for drugs.
Strategic Growth
- Funding: Raised $12M to enhance product offerings and expand customer base.
- Revenue Growth: Ranked No. 1819 on the 2024 Inc. 5000 with a three-year revenue growth of 287%.
- Regional Ranking: Ranked No. 90 on Inc. Magazine’s Northeast Region’s Fastest-Growing Private Companies.
New Leadership
- Scientific Advisory Board Chair: Appointment of Névine Zariffa, a leader in the pharmaceutical industry.
New Products and Features
- Generative AI: Implementing generative AI to enhance current AI capabilities in pharmaceutical research.
- Enhancements to Portfolio Optimizer: Updated methodologies to maintain high accuracy standards with modified clinical trial parameters.
Partnerships and Collaborations:
- Collaborations with leading global pharmaceutical companies for portfolio planning, business development, licensing strategies, and competitive intelligence.
- Active participation and sponsorship in industry conferences and events such as Intelligent Health, ESMO Annual Conference, and Why Summits.
Partnerships: No specific new partnerships mentioned.
For further inquiries or detailed information, please visit the Intelligencia AI official website or contact their business development team.
